Accueil / Formation Recherche / Publications / Publications Amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales

Publications Amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.


Comprehensive molecular characterization of a heavy chain deposition disease case.


Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury.


Animal models of monoclonal immunoglobulin-related renal diseases.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. Bridoux F et al. JAMA. 2017 Dec 5.

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants. Garnier C et al. Blood. 2017 Dec 21.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Dimopoulos M et al. J Clin Oncol. 2018 Feb 2.

[Classification and therapeutic management of monoclonal gammopathies of renal significance]. Javaugue V et al. Rev Med Interne. 2018 Mar.

Animal models of monoclonal immunoglobulin-related renal diseases. Sirac C et al. Nat Rev Nephrol. 2018 Apr.

Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Deshayes S et al. Clin Rheumatol. 2018 Apr.

Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury. Hudier L et al. Clin Kidney J. 2018 Apr.

Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Sanchorawala V et al. Blood. 2017 Aug 3;130(5):597-605.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Palladini G et al. Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743.

Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of
dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F et al. Eur J Cancer. 2017
May;76:183-187.

Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Mohty D et al. Clin Res Cardiol. 2017 May;106(5):331-340.

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Chauvet S et al. Blood 2017
 
The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Vignon M et al. Kidney Int 2017
 
Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F et al. Kidney Int. 2017
 
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Vignon M et al. Leukemia. 2017

ACTUALITÉS

Le Pr Eric Oksenhendler récompensé "Médecin de l'année 2018" pour son travail sur la maladie de Castleman

Le congrès des Rencontres RARE revient pour sa 6ème édition, les 5 & 6 novembre 2019
Cité des Sciences et de l'Industrie, Paris
Ouverture des candidatures pour l'ASH 2019 à Orlando
La filière MaRIH recherche deux internes "reporters" pour participer à l'ASH !
Voir toutes les actualités

AGENDA

Du 27-09-2019 au 29-09-2019 : 16èmes Journées de l’Association des Internes en Hématologie, Lyon


04-10-2019 : 7ème Journée régionale interactive maladies rares immuno-hématologiques MaRIH "Océan Indien", Saint-Denis (La Réunion)


04-10-2019 : Journée annuelle du centre de référence des aplasies médullaires acquises et constitutionnelles, Paris
Voir tout l'agenda